Posted in | News | Nanoelectronics

Intel Announces Sampling of 32 nm Process-Based New Phone Chip

MOBILE WORLD CONGRESS--Intel Corporation today announced a number of advancements to its mobile portfolio across a broad spectrum of silicon, software and connectivity, including the sampling of “Medfield,” the company’s 32nm phone chip.

The company also announced accelerated LTE platforms, a new MeeGo tablet user experience, the acquisition of Silicon Hive, and several new mobile investments and software development tools to aid in the delivery of premium Intel® architecture-based device experiences across multiple operating systems.

As the lines between computing and communications continue to blur, this mobile momentum builds on and complements Intel’s growing capabilities in mobility. Intel is accelerating plans to become the processor architecture of choice across a variety of smart device and market segments -- netbooks and laptops, cars, smart phones, tablets and smart TVs -- while addressing the evolving needs of device manufacturers, service providers, software developers and consumers around the world.

“The mobile Internet, with all of its complexity, presents tremendous opportunity and growth prospects for the industry at large,” said Anand Chandrasekher, Intel senior vice president and general manager of the company’s Ultra Mobility Group. “Through these efforts and others still to come, Intel is bringing the full weight of its resources, technology investment and the economics of Moore’s Law to drive down costs and power requirements for new markets, while delivering the leading-edge performance that the industry has come to expect from us.”

Source: http://www.intel.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.